Last mentioned: Mar 24, 2026
Missouri Stay Request
DOJ files request in Missouri court to pause litigation pending FDA review.
Legislative Action
Senator Josh Hawley introduces a Senate bill to outright ban the abortion pill.
Louisiana Request
DOJ asks Louisiana court to pause a similar lawsuit; request is largely ignored by the state.
Amended Complaint
AG Catherine Hanaway files amended complaint targeting mail-order abortion drugs.
Lawsuit Filed
Missouri, Kansas, and Idaho file suit against the FDA over mifepristone approval.
SCOTUS Ruling
Supreme Court dismisses challenge to mifepristone access on standing grounds, preserving status quo.
Retail Pharmacy Entry
Major chains CVS and Walgreens receive certification to dispense abortion pills.
Dobbs Decision
Supreme Court overturns Roe v. Wade, leading to state-level bans.
Telehealth Expansion
FDA permanently removes in-person dispensing requirements, allowing mail-order access.
Initial FDA Approval
FDA approves Mifepristone for medical termination of early pregnancy.
Medication abortion now accounts for the majority of pregnancy terminations in the U.S., driven by telehealth expansion and state shield laws. This shift has triggered a wave of regulatory counter-measures from opponents, focusing on the Comstock Act and FDA approval processes.
House Republicans have introduced legislation that would criminalize flushing fetal remains, mandating the use of 'catch kits' for medical abortions to prevent alleged water contamination. The bill represents a novel attempt to use environmental protection frameworks to restrict reproductive healthcare access and ban telehealth services.
The U.S. Department of Justice has requested federal courts in Missouri to pause litigation challenging the FDA's approval of mifepristone, citing an ongoing internal agency review. This tactical shift suggests a preference for administrative rulemaking over high-profile court battles as the administration navigates the legal complexities of reproductive health regulation.
This page surfaces every story mentioning mifepristone across our legal coverage. We track each entity's appearance over time so readers can trace how the narrative evolves — which developments are isolated incidents, which build into longer arcs, and which reframe how operators in the space think about the entity. Story selection uses the same multi-source verification gate applied across the rest of our coverage.
Read our editorial methodology for how we identify, deduplicate, and score entity references. Our glossary defines the technical terms used across stories on this page, and our trends index contextualizes individual developments against the longer-running legal beat. Cross-entity comparisons live on our compare view.
| What you see | What it tells you |
|---|---|
| Story count | Number of distinct stories where mifepristone was a primary or referenced actor. |
| Recency clustering | Whether mentions are concentrated in a recent window (a news cycle) or distributed (a sustained arc). |
| Sentiment distribution | Aggregate sentiment of the stories mentioning this entity, weighted by impact score. |
| Cross-niche links | When the same entity surfaces in our sibling networks, we link to those views to enrich context. |